Ads
related to: multiple myeloma kappa light chain- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Contact a Representative
assistantsage.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Flow cytometry is often used to establish the clonal nature of the plasma cells, which will generally express only kappa or lambda light chain. Cytogenetics may also be performed in myeloma for prognostic purposes, including a myeloma-specific fluorescent in situ hybridization and virtual karyotype. [citation needed]
Abnormal free light chain production has also been reported to be prognostic of a worse outcome in multiple myeloma [36] [37] [38] and chronic lymphocytic leukaemia. [39] An abnormal light-chain ratio has been defined as a kappa to lambda chain ratio of less than 0.26 or more than 1.65. [32]
Free immunoglobulin light chains secreted by neoplastic plasma cells, such as in multiple myeloma, can be called Bence Jones protein when detected in the urine, although there is a trend to refer to these as urinary free light chains. Increased levels of free Ig light chains have also been detected in various inflammatory diseases.
Bence Jones protein is a monoclonal globulin protein or immunoglobulin light chain found in the urine, with a molecular weight of 22–24 kDa. [1] Detection of Bence Jones protein may be suggestive of multiple myeloma, [2] or Waldenström's macroglobulinemia. [citation needed]
MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy that in 2023 has been assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer.
Serum protein electrophoresis showing a paraprotein (spike/peak in the gamma zone) in a patient with multiple myeloma.. A myeloma protein is an abnormal antibody (immunoglobulin) or (more often) a fragment thereof, such as an immunoglobulin light chain, that is produced in excess by an abnormal monoclonal proliferation of plasma cells, typically in multiple myeloma or Monoclonal gammopathy of ...
Ads
related to: multiple myeloma kappa light chainassistantsage.com has been visited by 10K+ users in the past month